{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T13:28:16Z","timestamp":1782221296742,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s15010-025-02679-6","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T16:20:23Z","timestamp":1762446023000},"page":"401-407","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Underexposure of linezolid in critically ill patients with extracorporeal membrane oxygenation (ECMO): results from a monocentric study including blood samples from 52 patients"],"prefix":"10.1007","volume":"54","author":[{"given":"Rainer","family":"H\u00f6hl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Rasshofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Kinzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fritz","family":"S\u00f6rgel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Hitzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Bertram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Steinmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"TDM Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"issue":"791\u2013815","key":"2679_CR1","first-page":"vii","volume":"23","author":"ME Levison","year":"2009","unstructured":"Levison ME, Levison JH. Pharmacokinetics and pharmacodynamics of antibacterial agents. Infect Dis Clin N Am. 2009;23(791\u2013815):vii.","journal-title":"Infect Dis Clin N Am"},{"key":"2679_CR2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/phar.1882","volume":"37","author":"MA Ha","year":"2017","unstructured":"Ha MA, Sieg AC. Evaluation of altered drug pharmacokinetics in critically ill adults receiving extracorporeal membrane oxygenation. Pharmacotherapy. 2017;37:221\u201335.","journal-title":"Pharmacotherapy"},{"key":"2679_CR3","first-page":"6","volume":"1","author":"D Milakovic","year":"2024","unstructured":"Milakovic D, Kovacevic T, Kovacevic P, Barisic V, Avram S, Dragic S, et al. Population pharmacokinetic model of linezolid and probability of target attainment in patients with COVID-19-associated acute respiratory distress syndrome on veno-venous extracorporeal membrane oxygenation-a step toward correct dosing. Pharmaceutics. 2024;1:6.","journal-title":"Pharmaceutics"},{"key":"2679_CR4","doi-asserted-by":"publisher","first-page":"5254","DOI":"10.1128\/AAC.00356-16","volume":"60","author":"M Taubert","year":"2016","unstructured":"Taubert M, Zoller M, Maier B, Frechen S, Scharf C, Holdt LM, et al. Predictors of inadequate linezolid concentrations after standard dosing in critically ill patients. Antimicrob Agents Chemother. 2016;60:5254\u201361.","journal-title":"Antimicrob Agents Chemother"},{"key":"2679_CR5","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1185\/03007990903512057","volume":"26","author":"GE Stein","year":"2010","unstructured":"Stein GE, Wells EM. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid. Curr Med Res Opin. 2010;26:571\u201388.","journal-title":"Curr Med Res Opin"},{"key":"2679_CR6","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.2147\/DDDT.S164515","volume":"12","author":"SMR Hashemian","year":"2018","unstructured":"Hashemian SMR, Farhadi T, Ganjparvar M. Linezolid: a review of its properties, function, and use in critical care. Drug Des Devel Ther. 2018;12:1759\u201367.","journal-title":"Drug Des Devel Ther"},{"key":"2679_CR7","unstructured":"EUCAST. Breakpoint tables for interpretation of MICs and zone diameters. 2025, Vol. 2025."},{"key":"2679_CR8","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.2165\/00003088-200342130-00004","volume":"42","author":"DJ Stalker","year":"2023","unstructured":"Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet. 2023;42:1129\u201340.","journal-title":"Clin Pharmacokinet"},{"key":"2679_CR9","doi-asserted-by":"publisher","first-page":"R148","DOI":"10.1186\/cc13984","volume":"18","author":"M Zoller","year":"2014","unstructured":"Zoller M, Maier B, Hornuss C, Neugebauer C, Dobbeler G, Nagel D, et al. Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study. Crit Care. 2014;18:R148.","journal-title":"Crit Care"},{"key":"2679_CR10","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","volume":"46","author":"MH Abdul-Aziz","year":"2020","unstructured":"Abdul-Aziz MH, Alffenaar JC, Bassetti M, Bracht H, Dimopoulos G, Marriott D, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. Intensive Care Med. 2020;46:1127\u201353.","journal-title":"Intensive Care Med"},{"key":"2679_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.967311","volume":"10","author":"B Lin","year":"2022","unstructured":"Lin B, Hu Y, Xu P, Xu T, Chen C, He L, et al. Expert consensus statement on therapeutic drug monitoring and individualization of linezolid. Front Public Health. 2022;10:967311.","journal-title":"Front Public Health"},{"key":"2679_CR12","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1111\/myc.13469","volume":"65","author":"R H\u00f6hl","year":"2022","unstructured":"H\u00f6hl R, Bertram R, Kinzig M, Haarmeyer GS, Baumg\u00e4rtel M, Geise A, et al. Isavuconazole therapeutic drug monitoring in critically ill ICU patients: a monocentric retrospective analysis. Mycoses. 2022;65:747\u201352.","journal-title":"Mycoses"},{"key":"2679_CR13","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ijantimicag.2011.05.007","volume":"38","author":"H Dong","year":"2011","unstructured":"Dong H, Wang X, Dong Y, Lei J, Li H, You H, et al. Clinical pharmacokinetic\/pharmacodynamic profile of linezolid in severely ill intensive care unit patients. Int J Antimicrob Agents. 2011;38:296\u2013300.","journal-title":"Int J Antimicrob Agents"},{"key":"2679_CR14","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.ijid.2020.02.044","volume":"93","author":"H Barrasa","year":"2020","unstructured":"Barrasa H, Soraluce A, Uson E, Sainz J, Martin A, Sanchez-Izquierdo JA, et al. Impact of augmented renal clearance on the pharmacokinetics of linezolid: advantages of continuous infusion from a pharmacokinetic\/pharmacodynamic perspective. Int J Infect Dis. 2020;93:329\u201338.","journal-title":"Int J Infect Dis"},{"key":"2679_CR15","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1186\/s13054-020-03397-1","volume":"24","author":"D K\u00fchn","year":"2020","unstructured":"K\u00fchn D, Metz C, Seiler F, Wehrfritz H, Roth S, Alqudrah M, et al. Antibiotic therapeutic drug monitoring in intensive care patients treated with different modalities of extracorporeal membrane oxygenation (ECMO) and renal replacement therapy: a prospective, observational single-center study. Crit Care. 2020;24:664.","journal-title":"Crit Care"},{"key":"2679_CR16","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.ijantimicag.2016.08.023","volume":"48","author":"D Cattaneo","year":"2016","unstructured":"Cattaneo D, Gervasoni C, Cozzi V, Castoldi S, Baldelli S, Clementi E. Therapeutic drug management of linezolid: a missed opportunity for clinicians? Int J Antimicrob Agents. 2016;48:728\u201331.","journal-title":"Int J Antimicrob Agents"},{"key":"2679_CR17","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.ijantimicag.2013.01.016","volume":"41","author":"FG De Rosa","year":"2013","unstructured":"De Rosa FG, Corcione S, Baietto L, Ariaudo A, Di Perri G, Ranieri VM, et al. Pharmacokinetics of linezolid during extracorporeal membrane oxygenation. Int J Antimicrob Agents. 2013;41:590\u20131.","journal-title":"Int J Antimicrob Agents"},{"key":"2679_CR18","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1093\/ajhp\/zxaa066","volume":"77","author":"P Nikolos","year":"2020","unstructured":"Nikolos P, Osorio J, Mohrien K, Rose C. Pharmacokinetics of linezolid for methicillin-resistant Staphylococcus aureus pneumonia in an adult receiving extracorporeal membrane oxygenation. Am J Health Syst Pharm. 2020;77:877\u201381.","journal-title":"Am J Health Syst Pharm"},{"key":"2679_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics13040373","author":"H Booke","year":"2024","unstructured":"Booke H, Friedrichson B, Draheim L, von Groote TC, Frey O, Rohr A, et al. No sequestration of commonly used anti-infectives in the extracorporeal membrane oxygenation (ECMO) circuit-an ex vivo study. Antibiotics (Basel). 2024. https:\/\/doi.org\/10.3390\/antibiotics13040373.","journal-title":"Antibiotics (Basel)"},{"key":"2679_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2022.106572","volume":"59","author":"SG Wicha","year":"2022","unstructured":"Wicha SG, Mair A, Chiriac U, Frey OR, Fuchs T, Gaasch M, et al. Population pharmacokinetics and toxicodynamics of continuously infused linezolid in critically ill patients. Int J Antimicrob Agents. 2022;59:106572.","journal-title":"Int J Antimicrob Agents"},{"key":"2679_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106949","volume":"62","author":"Q Liu","year":"2023","unstructured":"Liu Q, Li S, Xie F. Linezolid dosing in critically ill patients undergoing various modalities of renal replacement therapy: a pooled population pharmacokinetic analysis. Int J Antimicrob Agents. 2023;62:106949.","journal-title":"Int J Antimicrob Agents"},{"key":"2679_CR22","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1128\/AAC.01608-12","volume":"57","author":"C Tascini","year":"2013","unstructured":"Tascini C, Di Paolo A, Poletti R, Flammini S, Emdin M, Ciullo I, et al. Daptomycin concentrations in valve tissue and vegetation in patients with bacterial endocarditis. Antimicrob Agents Chemother. 2013;57:601\u20132.","journal-title":"Antimicrob Agents Chemother"},{"key":"2679_CR23","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1093\/jac\/dkae171","volume":"79","author":"LC Zhang","year":"2024","unstructured":"Zhang LC, Li QY, Zhang YQ, Shan TC, Li Y, Li YH, et al. Population pharmacokinetics of daptomycin in critically ill patients receiving extracorporeal membrane oxygenation. J Antimicrob Chemother. 2024;79:1697\u2013705.","journal-title":"J Antimicrob Chemother"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02679-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-025-02679-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02679-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T08:39:59Z","timestamp":1770021599000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-025-02679-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2679"],"URL":"https:\/\/doi.org\/10.1007\/s15010-025-02679-6","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"assertion":[{"value":"12 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JS received honoraria for lectures from Gilead Sciences and Pfizer. RH received honoraria for lectures from Gilead Sciences, Infectopharm, MSD, Pfizer and Shionogi. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical review and approval was granted by the institutional review board at Klinikum N\u00fcrnberg (IRB-2025-01).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}},{"value":"Patient consent was waived, because this study was non-interventional and retrospective and measurements were part of clinical routine.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}